Related Experiment Videos
[Molecular staging of prostatic cancer]
1Clinique Urologique, Hôpital Bichat, Paris, France.
Summary
Current molecular staging for prostate cancer using RT-PCR shows promise but lacks standardization. Reliable and reproducible methods are needed before influencing treatment decisions for patients with localized prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Medical Diagnostics
Context:
- Current staging methods for prostate cancer are imperfect, leading to understaging in about 30% of localized cases.
- Reverse Transcription Polymerase Chain Reaction (RT-PCR) is explored as a sensitive tool for detecting circulating prostatic cells for molecular staging.
- Existing literature presents contradictory results regarding RT-PCR's efficacy in detecting prostate cancer cells.
Purpose:
- To critically review and discuss the literature on RT-PCR for detecting circulating prostate cancer cells.
- To evaluate the potential of RT-PCR as a molecular staging tool for prostate cancer.
- To assess the reliability and reproducibility of RT-PCR in routine clinical practice for prostate cancer management.
Summary:
- RT-PCR shows potential for detecting circulating prostate-specific antigen (PSA) or prostate-specific membrane antigen (PSMA)-positive cells.
- Significant variability exists in RT-PCR methodologies (equipment, primers, cycles, nested vs. classical) hindering consensus.
- Contradictory findings also plague RT-PCR's use in early detection during post-prostatectomy follow-up.
Impact:
- Standardization of RT-PCR techniques is crucial for its reliable application in prostate cancer staging.
- Demonstrating the reproducibility of molecular techniques is necessary before they can guide therapeutic decisions.
- Further research is needed to establish consistent and dependable RT-PCR protocols for clinical use.